Press release Biocartis Group NV: Biocartis Announces Presentation
of Three Idylla™ Studies at 32nd European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID)
PRESS RELEASE: 25 April 2022, 07:00 CEST
Biocartis Announces
Presentation of Three
Idylla™ Studies at 32nd European Congress
of Clinical Microbiology & Infectious Diseases
(ECCMID)
Mechelen, Belgium, 25
April 2022
– Biocartis Group NV (the ‘Company’ or
‘Biocartis’), an innovative molecular diagnostics company (Euronext
Brussels: BCART), today announces that three Idylla™ study posters,
of which two on the SeptiCyte® RAPID (developed in
collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2
Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), were
presented at the 32nd European Congress of Clinical Microbiology
& Infectious Diseases (ECCMID) between 23 – 26 April in Lisbon,
Portugal.
Herman Verrelst, Chief Executive Officer
of Biocartis, commented: “We are pleased to see three
study presentations on Idylla™ tests during this annual conference
of Europe’s leading society in clinical microbiology and infectious
diseases. The studies underline once more that the strength of
Idylla™ tests lies in the combination of both fast and accurate
results, enabling rapid clinical decision-making. Especially in the
case of sepsis, this can save lives. Finally, these studies show
how Idylla™ testing can be easily integrated within the routine
diagnostic process of hospitals.”
The first study1 (abstract #04729) was presented
in a poster session and evaluated whether SeptiCyte® RAPID could be
used as a triage tool for COVID-19 patients at a hospital2 in
France. Results demonstrated SeptiCyte® RAPID’s ability to
distinguish between COVID-19 patients showing higher extents of
lung damage as defined by lung CT scans (critical and severe) from
those with a milder presentation (mild, moderate, absent). The
SeptiScore®, as evaluated by SeptiCyte® RAPID, of critical and
severe patients in the ICU was higher relative to the moderate and
mild cases not in ICU. Also, the utility of the SeptiScore® for
longitudinal monitoring of patients with severe cases was suggested
by repeat testing on selected patients.
Rollie Carlson, Ph.D., Chief Executive
Officer of Immunexpress, added: “During
the COVID-19 pandemic, sepsis incidence increased. This study shows
that the SeptiCyte® RAPID on the Idylla™ platform can distinguish
COVID-19 cases with severe or critical presentation on a CT scan
from those with mild or moderate presentation. This is essential to
identify and triage patients in need of timely sepsis specific
medical care.”
The second study3 (abstract #04693) was
presented in an online poster session and evaluated the performance
of SeptiCyte® RAPID as an everyday tool in the management of ICU
patients at two clinical sites in Portugal4. Results demonstrated a
significant correlation between the diagnosis of sepsis and an
elevated SeptiScore®. From eight patients diagnosed with either
septic shock or sepsis, six had elevated scores and two had
intermediate-elevated scores. The study concluded that the
SeptiCyte® score pinpointed all cases while also suggesting the
diagnosis of patients of whom sepsis was not detected by most
traditional methods, found to be severely lacking in this
setting5.
Severe COVID-19 can be considered an example of
viral sepsis. Sepsis is a life-threatening medical emergency
associated with high morbidity and mortality, making early sepsis
detection of utmost importance. Today’s gold standard for detecting
sepsis in the laboratory setting is microbiological culture
identification. However, the prediction of positive blood culture
results remains a very difficult task since positive blood culture
results in approx. only 20% of the cases6 due to low sensitivity.
Also, it can take days to report results. Studies such as the ones
presented at ECCMID show that newer methods such as the SeptiCyte®
RAPID, running on Biocartis’ Idylla™ platform, combine fast and
accurate results, enabling rapid clinical decision-making.
Finally, the third study7 (abstract #04963),
presented in a poster session, highlighted the performance data of
the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™
SARS-CoV-2/Flu/RSV Panel (CE-IVD) and concluded that both Idylla™
assays provide quick, accurate results with minimal hands-on-time,
making them suitable for an NHS (National Health Service, UK)
setting.
--- END ---
More information: Renate DegraveHead of
Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com
tel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for COVID-19, flu,
RSV and sepsis. More information: www.biocartis.com. Follow us
on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
1 Victor Gravrand et al., ‘SeptiCyte® RAPID in
COVID-19 severity stratification and triage’, first published
online during ECCMID, 23-26 April 2022, Lisbon (Portugal). The
study was supported by the Biomedical Advanced Research and
Development Authority (BARDA)2 94 COVID-19 positive patients were
evaluated at Hospital Foch, Paris (France)3 João Antunes et al.,
‘Using SeptiCyte RAPID as an everyday tool in ICU patient care
management’, first published online during ECCMID, 23-26 April
2022, Lisbon (Portugal)4 The study enrolled 25 adults, 17 of whom
were post-surgery and 8 of whom were COVID-19 positive. Using
standard microbiological culture, presumptively causative pathogens
were identified in 48.6% of cases5 Due to the design of the study
and small sample cohort, further studies will be needed to finetune
the positioning of SeptiCyte® RAPID6 Previsdomini M, Gini M,
Cerutti B, Dolina M, Perren A. Predictors of positive blood
cultures in critically ill patients: a retrospective
evaluation. Croat Med J. 2012;53(1):30-39.
doi:10.3325/cmj.2012.53.307 Brookes et al., Comparative study
assessing the utility of a rapid based COVID-19 assay for use in a
clinical diagnostic laboratory, first published online during
ECCMID, 23-26 April 2022, Lisbon (Portugal). The aim was to compare
the Idylla™ SARS-CoV-2 Test and the Idylla™ SARS-CoV-2/Flu/RSV
Panel against the Genesig SARS-CoV-2 batch assay. The secondary aim
was to assess suitability in an NHS setting
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024